Treatment of lung cancer using a combination of anti-PD-1 antibodies and other anticancer agents

摘要

The present disclosure is a method of treating a subject suffering from lung cancer, wherein the subject specifically binds to a therapeutically effective amount of (a) a programmed cell death 1 (PD-1) receptor and PD-1 activity An anti-cancer agent that is an antibody that inhibits or an antigen-binding portion thereof; and (b) administering another anti-cancer agent. Other anti-cancer agents are used in the treatment of lung cancer or platinum doublet chemotherapy, EGFR targeted tyrosine kinase inhibitors, anti-VEGF antibodies, anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies or here Any other therapeutic agent disclosed in.